In conclusion, although further investigations are warranted to validate the findings, our study at least in part unveils the altered landscape in the ICC tumor ecosystem following ICB therapy and highlights the significance of targeting CAFs and SPP1+TAMs to guide a more rational immune-based therapy for ICC. The gene discussed is SPP1; the disease is intrahepatic cholangiocarcinoma.